Tempus AI (TEM) After CellCarta Deal And PRISM2 Validation Faces A Fresh Valuation Test

Simply Wall St.08-10

Tempus AI (TEM) is back in focus after CellCarta added the company to its CDx Commercialization Lab Network, linking Tempus Hub ordering to CellCarta testing and tightening access to oncology ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2658670176?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/9551728-choice1-main-header/1585186657000","is_english":true,"pubTime":"2026-08-10 00:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2658670176","market":"us","top_or_hot":-1,"title":"Tempus AI (TEM) After CellCarta Deal And PRISM2 Validation Faces A Fresh Valuation Test","media":"Simply Wall St.","content":"<div>\n<p>Tempus AI (TEM) is back in focus after CellCarta added the company to its CDx Commercialization Lab Network, linking Tempus Hub ordering to CellCarta testing and tightening access to oncology ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tem/tempus-ai/news/tempus-ai-tem-after-cellcarta-deal-and-prism2-validation-fac\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tempus AI (TEM) After CellCarta Deal And PRISM2 Validation Faces A Fresh Valuation Test</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTempus AI (TEM) After CellCarta Deal And PRISM2 Validation Faces A Fresh Valuation Test\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-08-10 00:30 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tem/tempus-ai/news/tempus-ai-tem-after-cellcarta-deal-and-prism2-validation-fac><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Tempus AI (TEM) is back in focus after CellCarta added the company to its CDx Commercialization Lab Network, linking Tempus Hub ordering to CellCarta testing and tightening access to oncology ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tem/tempus-ai/news/tempus-ai-tem-after-cellcarta-deal-and-prism2-validation-fac\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1861559042.SGD","symbol_name":"日兴方舟颠覆性创新基金B SGD","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tem/tempus-ai/news/tempus-ai-tem-after-cellcarta-deal-and-prism2-validation-fac","article_id":"2658670176","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/9551728-choice1-main-header/1585186657000"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tem/tempus-ai/news/tempus-ai-tem-after-cellcarta-deal-and-prism2-validation-fac","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2658670176","pubTimestamp":1786293017,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Tempus AI (TEM) is back in focus after CellCarta added the company to its CDx Commercialization Lab Network, linking Tempus Hub ordering to CellCarta testing and tightening access to oncology companion diagnostics for U.S. providers.\nSee our latest analysis for Tempus AI.\nTempus AI’s recent CellCarta partnership, PRISM2 publication and earnings update have arrived alongside a sharp 1-day share price return of 12.86% and a 7-day share price return of 18.65%. However, the year-to-date share...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1861559042.SGD":"日兴方舟颠覆性创新基金B SGD","BK4611":"AI医疗","HEAL":"Global X HealthTech ETF","TEMT":"2倍做多TEM ETF-Tradr","BK4121":"生命科学工具和服务","LU1861558580.USD":"日兴方舟颠覆性创新基金B","TEM":"Tempus AI","ARKG":"ARK Genomic Revolution ETF","BK4613":"AI应用软件"},"translate_title":"CellCarta 交易和 PRISM2 验证后的 Tempus AI (TEM) 面临新的估值测试","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TEMT":0.6,"TEM":1.98,"HEAL":0.6,"ARKG":0.6},"content_text":"Tempus AI (TEM) is back in focus after CellCarta added the company to its CDx Commercialization Lab Network, linking Tempus Hub ordering to CellCarta testing and tightening access to oncology companion diagnostics for U.S. providers. See our latest analysis for Tempus AI. Tempus AI’s recent CellCarta partnership, PRISM2 publication and earnings update have arrived alongside a sharp 1-day share price return of 12.86% and a 7-day share price return of 18.65%. However, the year-to-date share price return is down 16.53% and the 1-year total shareholder return is down 14.49%, suggesting recent momentum is building after a weaker stretch. If this mix of healthcare and AI appeals to you, it could be a good moment to widen your watchlist and check out 43 healthcare AI stocks After Tempus AI’s sharp move and the sizeable gap between its recent US$52.05 share price, the average analyst target near US$62.64 and a deeper intrinsic estimate, where does a reasonable view of fair value actually sit? AdvertisementMost Popular Narrative: 21% Undervalued Tempus AI’s most followed narrative sets a fair value of $65.90 per share, above the recent $52.05 close. This puts a clear spotlight on the gap.  Tempus AI isn't simply an AI software business (not another ChatBot). It is building a healthcare data platform where diagnostics, genomic testing, clinical data, and AI applications reinforce each other through a powerful network effect.  Read the complete narrative. Want to see why this fair value sits meaningfully above today’s Tempus AI share price? The narrative highlights expanding revenue, rising margins, and a richer future earnings multiple. Result: Fair Value of $65.90 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, Tempus AI still faces real pressure points, including ongoing net losses of US$254.43m and the risk of any slowdown in its healthcare data partnerships or AI product uptake. Find out about the key risks to this Tempus AI narrative. Another View: Tempus AI Looks Expensive On Sales While the user narrative points to roughly 25% upside for Tempus AI, the current P/S ratio of 6.6x tells a more cautious story. It sits above both peers at 5.5x and the US Life Sciences industry at 4.1x, even though the fair ratio sits higher at 7.7x. That gap leaves a mix of perceived upside and valuation risk. Which signal do you put more weight on? For a closer look at how this sales based view lines up with the fair ratio and peers, See what the numbers say about this price — find out in our valuation breakdown. NasdaqGS:TEM P/S Ratio as at Aug 2026Next Steps Given the mixed signals around Tempus AI, consider whether the balance of risk and reward matches your own tolerance and time horizon. To pressure test your view against the underlying data, take a closer look at the 2 key rewards and 1 important warning sign Looking for more investment ideas beyond Tempus AI? If Tempus AI has sharpened your interest in data driven investing, do not stop here. Use focused stock lists to uncover fresh opportunities that fit your style.  Target potential mispricing by scanning companies that appear to offer strong quality at appealing valuations through the 52 high quality undervalued stocks. Strengthen your income stream by reviewing businesses with higher yields and robust payouts using the 8 dividend fortresses. Prioritise financial resilience by checking companies that feature stronger balance sheets and fundamentals inside the solid balance sheet and fundamentals stocks screener (48 results).   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if Tempus AI might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2658670176","isCrawlerRequest":true}